Octreotide
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Immediate-release: Administer subcutaneously or intravenously (50 to 100 mcg two to three times daily). For acute variceal bleeding: IV bolus 50 mcg followed by continuous IV infusion of 50 mcg/hr for 2 to 5 days. Depot LAR: Administer by deep intragluteal intramuscular (IM) injection only, once every 4 weeks by a healthcare professional.
⚠️ Side Effects
Common: Injection site pain, diarrhea, abdominal cramps, nausea, flatulence, cholelithiasis (gallstones or biliary sludge in up to 50% with chronic therapy), transient hypo- or hyperglycemia. Rare/Severe: Bradycardia, conduction abnormalities, and acute pancreatitis.
🛡️ Safety Warnings
Chronic therapy induces gallstones or biliary sludge due to inhibition of gallbladder contractility; perform periodic gallbladder ultrasound. Modulates glycemic hormones; close blood glucose monitoring required in diabetic patients. LAR depot is strictly for intragluteal IM injection.
Jan Aushadhi Products containing Octreotide
Found 4 generic formulation(s) containing this active ingredient.
Octreotide long acting release Injection 20mg (Lyophilised)
Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.
Octreotide long acting release Injection 30mg (Lyophilised)
Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.
Octreotide injection 50 mcg
Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.
Octreotide injection 100mcg
Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Octreotide.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Octreotide long acting release Injection 20mg (Lyophilised) | Vial | Under Process | N/A | N/A | N/A |
| Octreotide long acting release Injection 30mg (Lyophilised) | Vial | ₹12000.00 | N/A | N/A | N/A |
| Octreotide injection 50 mcg | 1ml Ampoule | ₹80.00 | OCTRIDE, OCTRIDE LAR, ACTIDE | ₹4033.67 | 98% Save |
| Octreotide injection 100mcg | 1ml Ampoule | ₹140.00 | OCTRIDE | ₹495.00 | 72% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Octreotide generics.